These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 34655298

  • 1. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
    Wang D, Bao H.
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):31-40. PubMed ID: 34655298
    [Abstract] [Full Text] [Related]

  • 2. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.
    Oncogene; 2018 Feb 08; 37(6):821-832. PubMed ID: 29059158
    [Abstract] [Full Text] [Related]

  • 3. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
    Liu Y, Zhao R, Fang S, Li Q, Jin Y, Liu B.
    Fundam Clin Pharmacol; 2021 Feb 08; 35(1):156-164. PubMed ID: 32446293
    [Abstract] [Full Text] [Related]

  • 4. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, Gelbert LM, Shannon HE, Sanchez-Martinez C, De Dios A.
    Drug Metab Dispos; 2015 Sep 08; 43(9):1360-71. PubMed ID: 26149830
    [Abstract] [Full Text] [Related]

  • 5. Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine.
    Li Y, Sung Y, Choi YE, Choi Y, Goh SH.
    Int J Mol Sci; 2024 Jul 05; 25(13):. PubMed ID: 39000513
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
    Oshiro H, Tome Y, Miyake K, Higuchi T, Sugisawa N, Kanaya F, Nishida K, Hoffman RM.
    Anticancer Res; 2021 Jul 05; 41(7):3287-3292. PubMed ID: 34230123
    [Abstract] [Full Text] [Related]

  • 8. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J.
    Breast Cancer; 2021 Jan 05; 28(1):206-215. PubMed ID: 32860163
    [Abstract] [Full Text] [Related]

  • 9. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY, Kok ZH, Bui NL, Xiang X, Wong AL, Yong WP, Sethi G, Lobie PE, Wang L, Goh BC.
    Pharmacol Res; 2020 Jun 05; 156():104686. PubMed ID: 32068118
    [Abstract] [Full Text] [Related]

  • 10. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
    Bouclier C, Simon M, Laconde G, Pellerano M, Diot S, Lantuejoul S, Busser B, Vanwonterghem L, Vollaire J, Josserand V, Legrand B, Coll JL, Amblard M, Hurbin A, Morris MC.
    Theranostics; 2020 Jun 05; 10(5):2008-2028. PubMed ID: 32104498
    [Abstract] [Full Text] [Related]

  • 11. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
    O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ.
    Mol Cancer Ther; 2018 May 05; 17(5):897-907. PubMed ID: 29483214
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD.
    PLoS One; 2021 May 05; 16(6):e0252927. PubMed ID: 34138895
    [Abstract] [Full Text] [Related]

  • 16. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
    Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, Blosser W, Gupta S, Stewart J, Webster Y, Dempsey J, VanWye AB, Ebert P, Iversen P, Olsen JB, Gong X, Buchanan S, Houghton P, Stancato L.
    Clin Cancer Res; 2018 Dec 01; 24(23):6028-6039. PubMed ID: 30131386
    [Abstract] [Full Text] [Related]

  • 17. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
    Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A.
    Invest New Drugs; 2014 Oct 01; 32(5):825-37. PubMed ID: 24919854
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
    Aliagas E, Alay A, Martínez-Iniesta M, Hernández-Madrigal M, Cordero D, Gausachs M, Pros E, Saigí M, Busacca S, Sharkley AJ, Dawson A, Palmero R, Ruffinelli JC, Padrones S, Aso S, Escobar I, Ramos R, Llatjós R, Vidal A, Dorca E, Varela M, Sánchez-Céspedes M, Fennell D, Muñoz-Pinedo C, Villanueva A, Solé X, Nadal E.
    Br J Cancer; 2021 Nov 01; 125(10):1365-1376. PubMed ID: 34588615
    [Abstract] [Full Text] [Related]

  • 19. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.
    Cell Oncol (Dordr); 2019 Oct 01; 42(5):705-715. PubMed ID: 31250364
    [Abstract] [Full Text] [Related]

  • 20. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
    Kumarasamy V, Vail P, Nambiar R, Witkiewicz AK, Knudsen ES.
    Cancer Res; 2021 Mar 01; 81(5):1347-1360. PubMed ID: 33323381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.